Citius Pharmaceuticals (NASDAQ:CTXR) and Klotho Neurosciences (NASDAQ:KLTO) Head-To-Head Review

Klotho Neurosciences (NASDAQ:KLTO) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Valuation & Earnings

This table compares Klotho Neurosciences and Citius Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Klotho Neurosciences	N/A	N/A	-$6.15 million	($0.32)	-1.64
Citius Pharmaceuticals	N/A	N/A	-$37.43 million	($2.45)	-0.29

Klotho Neurosciences is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Klotho Neurosciences and Citius Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Klotho Neurosciences	1	0	0	0	1.00
Citius Pharmaceuticals	1	2	1	0	2.00

Citius Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 733.33%. Given Citius Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Klotho Neurosciences.

Volatility & Risk

Klotho Neurosciences has a beta of 9.08, meaning that its share price is 808% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.

Profitability

This table compares Klotho Neurosciences and Citius Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Klotho Neurosciences	N/A	-201.60%	-171.30%
Citius Pharmaceuticals	N/A	-49.34%	-28.64%

Institutional & Insider Ownership

20.1% of Klotho Neurosciences shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 9.9% of Klotho Neurosciences shares are owned by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Citius Pharmaceuticals beats Klotho Neurosciences on 6 of the 11 factors compared between the two stocks.

About Klotho Neurosciences

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.